SSR149415
Sponsors
Sanofi
Conditions
Anxiety DisordersDepressive Disorder
Phase 2
An Eight-Week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Major Depressive Disorder
CompletedNCT00358631
Start: 2006-07-31End: 2007-12-31Updated: 2009-04-13
An Eight-Week Study Evaluating the Efficacy of Two Fixed Doses (250 mg Twice Daily and 100 mg Twice Daily) of SSR149415 in Patients With Major Depressive Disorder
CompletedNCT00361491
Start: 2006-08-31End: 2007-09-30Updated: 2009-01-16
An Eight-week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Generalized Anxiety Disorder
CompletedNCT00374166
Start: 2006-08-31End: 2008-02-29Updated: 2016-05-25